



**ASX ANNOUNCEMENT**

29 January 2007

## **World Wide Exclusive Laboratory Supply Contract Signed**

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has achieved a major business development milestone by signing a world wide exclusive agreement with Invitrogen Corporation (Nasdaq: IVGN), a provider of essential life science technologies for disease research and drug discovery, for the promotion and sale of VitroGro®. VitroGro® is used in live cell research for the production of proteins and development of new health treatments.

This agreement will result in the world wide distribution of the synthetic VitroGro® protein platform for use by biomedical scientists in research institutions and pharmaceutical and biotechnology companies, who need, or prefer to use, a completely synthetic, defined media for the growth of cells and production of proteins.

Headquartered in Carlsbad, California, Invitrogen provides products and services that support academic and government research institutions, as well as pharmaceutical and biotechnology companies. Products are sold directly in most major countries and through distributors or agents in all others. In 2007, the company is celebrating 20 years of accelerating scientific discovery, including advancements in stem cell and chemically defined media.

The VitroGro® protein platform that will be sold world wide by Invitrogen will be manufactured to Good Manufacturing Practice (GMP) standard. This will substantially simplify experimental work on future health and medical therapies developed or tested with live cells by making regulatory approval for these treatments simpler, faster and less expensive.

CEO of Tissue Therapies Ltd., Dr Steven Mercer said, "This is an exciting day for Tissue Therapies. We are delighted to have formalised a world wide sales and distribution agreement for GMP VitroGro® with Invitrogen, one of the most sophisticated, innovative and well respected life science companies in the world. We could not wish for a better partner to promote VitroGro® to pharmaceutical and biotechnology companies, as well as academic and government research institutions."

"We believe VitroGro® could provide an excellent animal-origin free substrate for feeder-free culture of stem cells," said Joydeep Goswami, Vice President, Stem Cells and Regenerative Medicine at Invitrogen. "It is a natural fit with our efforts to provide a broad portfolio of serum-free and defined products for stem cell culture to stem cell researchers around the globe."

Cont/ 2...

The demand for completely synthetic, defined media for biologic research is expanding rapidly. There are many practical and technical advantages to biomedical scientists in using cell growth media that contain only known, characterised, synthetic proteins, particularly when the media is made to GMP standards.

Dr Mercer explained, "To the best of our knowledge, the VitroGro® media to be sold by Invitrogen is the only completely synthetic, defined, cell media available in the world today in which human stem cells can be grown. This gives us a significant competitive advantage, particularly when it is also made to GMP standards."

Under the agreement, Tissue Therapies will supply VitroGro® manufactured under contract, at an agreed supply price to Invitrogen. Additional Tissue Therapies revenue will be generated by half yearly royalty payments as well as additional one time payments on the achievement of agreed milestones. Sales are expected to start early in the second half of calendar 2007.

Further information:           Dr Steven Mercer  
  CEO, Tissue Therapies Limited  
  Telephone: 07 3221 0140  
  
  Email: [s.mercer@tissuetherapies.com](mailto:s.mercer@tissuetherapies.com)

Cont/ 3...

## About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

**More information:** [www.tissuetherapies.com](http://www.tissuetherapies.com)

## About Invitrogen

Invitrogen Corporation (Nasdaq: **IVGN**) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition.

The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world.

Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company is celebrating 20 years of accelerating scientific discovery. Invitrogen globally employs approximately 5,000 scientists and other professionals and had revenues of more than \$1.2 billion in 2006.

For more information, visit [www.invitrogen.com](http://www.invitrogen.com)